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OBJECTIVE—Streptozotocin (STZ) is the most widely used di-
abetogenic agent in animal models of islet transplantation. However,
the immunomodifying effects of STZ and the ensuing hyperglycemia
on lymphocyte subsets, particularly on T regulatory cells (Tregs),
remain poorly understood.
RESEARCH DESIGN AND METHODS—This study evaluated
how STZ-induced diabetes affects adaptive immunity and the
consequences thereof on allograft rejection in murine models of
islet and skin transplantation. The respective toxicity of STZ and
hyperglycemia on lymphocyte subsets was tested in vitro. The
effect of hyperglycemia was assessed independently of STZ in
vivo by the removal of transplanted syngeneic islets, using an
insulin pump, and with rat insulin promoter diphtheria toxin
receptor transgenic mice.
RESULTS—Early lymphopenia in both blood and spleen was
demonstrated after STZ administration. Direct toxicity of STZ on
lymphocytes, particularly on CD8+ cells and B cells, was shown
in vitro. Hyperglycemia also correlated with blood and spleen
lymphopenia in vivo but was not lymphotoxic in vitro. Indepen-
dently of hyperglycemia, STZ led to a relative increase of Tregs
in vivo, with the latter retaining their suppressive capacity in
vitro. The higher frequency of Tregs was associated with Treg
proliferation in the blood, but not in the spleen, and higher
blood levels of transforming growth factor-b. Finally, STZ ad-
ministration delayed islet and skin allograft rejection compared
with naive mice.
CONCLUSIONS—These data highlight the direct and indirect
immunosuppressive effects of STZ and acute hyperglycemia,
respectively. Thus, these results have important implications
for the future development of tolerance-based protocols and
their translation from the laboratory to the clinic. Diabetes
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Many animal models of diabetes depend on theadministration of diabetogenic drugs such asstreptozotocin (STZ) or alloxan. These aretoxic glucose analogs that target pancreatic
b-cells via GLUT2 transporter uptake. Because of the
simplicity and reproducibility of diabetes induction with
STZ, a highly stable glucosamine-nitrosourea compound, it
represents by far the most widely used model (1). Indeed,
among 131 analyzed articles published in 2010 on murine
islet transplantation, 100 (76.3%) used STZ to induce di-
abetes, whereas 21 (16%) were performed in models of
spontaneous diabetes (mostly NOD mice), 3 (2.3%) in-
volved alloxan, 5 (3.8%) relied on transplanted islets in
nondiabetic mice, and 2 (1.5%) used alternative ways for
diabetes induction. Whereas STZ is known to target b-cells
via the transporter GLUT2, it is not speciﬁc, since the
kidney and liver are also susceptible to STZ toxicity (1).
Moreover, several groups have described immunomodify-
ing effects of STZ both in vitro and in vivo, although the
confounding impact of the induced hyperglycemia was not
clearly distinguished (2–6). Luo et al. (7) reported that
hyperglycemia, potentially via an increased level of corti-
costeroids, causes a rapid depletion in thymocytes and
splenic T cells followed by homeostatic T-cell proliferation.
However, the exact mechanisms leading to the observed
immunosuppression after STZ administration, especially the
effect on different lymphocyte subpopulations, including
T regulatory cells (Tregs), remain elusive.
One of the major goals in islet transplantation (Tx) re-
search is to ﬁnd strategies to obviate the need for lifelong
immunosuppression that is toxic to the b-cells and detri-
mental to the host (8). Indeed, using STZ-induced diabetes
models, novel immunosuppressive and tolerance induction
protocols for allogeneic as well as xenogeneic islet Tx
have demonstrated long-term graft survival (9,10). How-
ever, many costimulation blockade–based Tx tolerance
protocols that are successful in chemically induced di-
abetic mice failed to produce long-term graft tolerance in
NOD mice or in other Tx models such as skin Tx, with the
latter being considered as one of the most stringent models.
The underlying autoimmunity directed against b-cells, the
mode of Tx, and the skin-speciﬁc antigen–presenting cells all
have been put forward to explain the observed resistance to
Tx tolerance (10,11). Another possible explanation for these
apparent differences is that immunosuppression related to
STZ-induced diabetes could result in an overestimation of the
efﬁcacy of tolerance induction. Consistent with this notion,
a protocol targeting costimulation that induced tolerance
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in STZ-induced diabetic recipients was unable to induce
tolerance in nondiabetic recipients (7). Thus, STZ and/or
the ensuing hyperglycemia seem to downregulate the
adaptive immune response against islet grafts.
In the past few years, Tregs were reported to play a key
role in long-term islet graft tolerance (12–15). However,
none of these studies addressed the possible effect of STZ
administration and the ensuing hyperglycemia on Tregs.
Using a rat-to-mouse islet Tx model, we recently reported
an increase of Tregs in lymphoid organs and within grafts
of tolerant mice treated with rapamycin and anti-CD154
monoclonal antibody (mAb), suggesting a critical role for
Tregs in the induction phase of tolerance (9,16). The aim of
the current study was to analyze whether STZ-induced
diabetes leads to changes in Treg numbers and function
and whether this affects subsequent immune responses
using models of islet and skin Tx.
RESEARCH DESIGN AND METHODS
C57BL/6 (H2b) mice, 6–10 weeks of age, were used as recipients (Centre
d’Elevage R. Janvier, Le Genest-St-Isle, France). BALB/c (H2d) mice were used as
islet donors and BL/6xDBA/2 F1 (H2bxH2d) as skin donors (Janvier). Rat insulin
promoter diphtheria toxin receptor (RIP-DTR) transgenic mice were provided by
Pedro Herrera (Geneva University Medical School, Geneva, Switzerland), and
Foxp3 green ﬂuorescent protein (GFP) knock-in mice were provided by David
Scotts (Center for Vascular and Inﬂammatory Diseases, University of Maryland
at Baltimore, Baltimore, MD). The Foxp3 knock-in mice have the GFP coding
sequence inserted in the ﬁrst exon of the Foxp3 gene and have been backcrossed
on a C57BL/6 background. Animals were maintained in conventional housing
facilities. Experiments involving animals were performed in compliance with the
relevant laws according to the Geneva Medical Faculty’s Veterinary Authorities.
Islet and skin Tx. C57BL/6 mice were rendered diabetic by a single in-
traperitoneal injection of STZ (220mg/kg; Sigma-Aldrich, St. Louis,MO) andwere
transplanted 72 h later. Blood glucose levels were monitored three times weekly
using a blood glucose meter (Precision Q.I.D, MediSense; Abbott Laboratories,
Bedford, MA). Only mice with blood glucose levels.17 mmol/L were used for Tx.
BALB/c pancreatic islets were isolated as previously described (9). A total of 400
islet equivalents were transplanted under the left kidney capsule. Blood glucose
levels of,11 mmol/L on 2 consecutive days deﬁned successful islet function. For
skin Tx, full-thickness tail skin was grafted onto the ﬂank of the recipients. Graft
sites were protected under sterile gauze and plaster until day 10, observed daily
afterward, and considered rejected when no viable skin remained.
Experimental design. STZ was solubilized in citrate buffer and used in vitro at
a concentration of 4.4 mmol/L. RIP-DTR transgenic mice were injected with 126
ng i.p. diphtheria toxin (DT) on days 0, 3, and 4 as previously described (17).
Insulin pumps (Linbit; LinShin Canada, Inc., Toronto, Ontario, Canada) were
implanted subcutaneously in STZ-induced diabetic mice 3 days after STZ ad-
ministration and allowed a sustained release of insulin (0.1 units/day) for .30
days. Anti-CD154 mAb (MR1, hamster antimouse CD154 mAb [CD40 L]; Bio
Express, West Lebanon, NH) diluted in PBS (Sigma-Aldrich) was administered
intraperitoneally at 0.5 mg per mouse on days 0, 2, and 4 after Tx. The fol-
lowing experimental groups were performed:
1) STZ-induced diabetic C57BL/6 mice transplanted with syngeneic islets on
day 3 post-STZ administration (+/2) nephrectomy on day 60 (n = 7)
2) DT-induced diabetic RIP-DTR mice (n = 4)
3) RIP-DTR control mice without DT treatment (n = 4)
4) STZ-induced diabetic C57BL/6 mice treated with an insulin pump starting
on day 3 (n = 4)
5) Nondiabetic C57BL/6 mice transplanted with allogeneic BALB/c islets
(n = 3)
6) STZ-induced diabetic C57BL/6 mice transplanted with allogeneic BALB/c
islets (n = 3)
7) STZ-induced diabetic C57BL/6 mice treated with an insulin pump (day 3)
and grafted with BL/6xDBA/2 F1 skin (day 3) (n = 7)
8) Nondiabetic C57BL/6 mice grafted with BL/6xDBA/2 F1 skin (day 3) (n = 8)
9) MR1-treated STZ-induced diabetic C57BL/6 mice treated with an insulin pump
(day 3) and MR1 and grafted with BL/6xDBA/2 F1 skin (day 3) (n = 7)
10) MR1-treated nondiabetic C57BL/6 mice grafted with BL/6xDBA/2 F1 skin
(day 3) (n = 11)
Blood leukocytes analysis. Blood was harvested from the tail vein into
heparinized tubes. White blood cell (WBC) counts and differentials were an-
alyzed using a pocH-100i hematology analyzer (Sysmex, Mundelein, IL), which
analyzed percent ratio of small WBCs (SCR, lymphocytes), middleWBCs (MCR,
monocytes), and large WBCs (LCR, granulocytes). Alternatively, absolute
numbers of WBCs were counted in a Neubauer chamber after red blood lysis
using Zapoglobulin (Beckam Coulter, Fullerton, CA).
Flow cytometry. Blood samples were analyzed on days 3, 7, and 12 after STZ
administration, and splenocytes were harvested at day 3 or 13 after STZ ad-
ministration. Cells were stained with anti-CD4 ﬂuorescein isothiocyanate
(FITC) or allophycocyanin (APC) (RM4–5; eBioscience, San Diego, CA), anti-
CD25 APC (PC61.5; eBioscience), anti-Foxp3 phycoerythrin (PE) (FJK16s;
eBioscience), anti-CD3 FITC (eBioscience), and anti-CD8 PE (eBioscience). All
samples were stained, ﬁxed, and permeabilized according to the eBioscience’s
instructions described in the mouse regulatory T-cell staining kit. Isotype
control antibodies were purchased from Becton Dickinson (Franklin Lakes,
NJ) (rat IgG2a FITC, rat IgG2a PE, rat IgG1 APC, and rat IgG2b APC mAb).
FIG. 1. Diabetes induction with STZ diminishes the absolute numbers of splenocytes. A: Blood glucose levels (mmol/L).○, STZ-induced diabetic mice;
□, naive mice. B: Weight (g) of C57BL/6 mice after STZ administration. ○, STZ-induced diabetic mice; □, naive mice. C: Absolute numbers of
splenocytes 3 (D3) and 13 (D13) days after STZ compared with naive mice (n = 5). The median and the range are shown and were analyzed with
a nonparametric Kruskal-Wallis test. D: Three spleens of STZ-induced diabetic mice at day 13 compared with naive mice are shown. A P value
inferior to 0.05 was considered statistically signiﬁcant (*P < 0.05, **P < 0.01).
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Proliferating cells were stained with PE Cy7 anti-CD4, PerCP anti-CD8, APC
anti-CD25, and then ﬁxed and permeabilized with Cytoﬁx/Cytoperm and Perm/
Wash buffers (eBioscience) and stained with Ki67/isotype control (Becton
Dickinson, Franklin Lakes, NJ ) and anti-Foxp3 (eBioscience). For determi-
nation of cell death/apoptosis, Annexin V and 7AAD were purchased from
Becton Dickinson. Data were collected on a FACScanto (Becton Dickinson).
All data were analyzed using Flowjo software (version 8.7.3; TreeStar, Inc.,
Ashland, OR).
In vitro proliferation and suppression assays. For proliferation assays,
0.2 3 106 splenocytes were stimulated with concanavalin A (3 mg/mL),
TABLE 1
Blood repartition after STZ administration
Peripheral
blood WBC (103/mL) SCR (%) MCR (%) LCR (%) RBC (106/mL)
Hemoglobin
(g/dL) n
Naive 18.9 6 (10.5/23.6) 93.2 6 (89.5/96.6) 2.8 6 (2.1/5.4) 3.7 6 (0.9/6) 11.43 6 (10.4/12.4) 15.9 6 (14.1/17) 11
Six h 11.7 6 (10.4/13.7) 80.9 6 (73.2/89.5) 10 6 (7.4/16.7) 8.7 6 (3.1/10.1) 11.5 6 (10.2/12.7) 15.6 6 (14.7/16.8) 6
Day 2 7.9 6 (6.8/10) 83.9 6 (81.4/86.8) 6.4 6 (4.3/7.8) 9.7 6 (7.6/11.9) 10 6 (9.5/10.8) 14 6 (13.6/15) 6
Day 5 7.6 6 (5.1/10.6) 84.2 6 (71.3/88.3) 6.9 6 (5.3/12.5) 8.9 6 (6.4/16.2) 9.9 6 (9.3/10.6) 14 6 (12.5/14.1) 5
Day 7 9.6 6 (5.5/11.2) 80.2 6 (70.3/88.5) 8.3 6 (5.5/11.8) 11.1 6 (4.9/17.9) 9.8 6 (9/10.7) 13.7 6 (12.5/14.3) 6
Day 12 8.2 6 (7.1/10.3) 88 6 (83.8/91.9) 5.1 6 (3.2/8.4) 6.9 6 (4.9/11.9) 10.1 6 (9.2/11.8) 13.9 6 (12.8/16) 4
Absolute numbers of WBCs and erythrocytes (RBC); percent ratio of SCR (lymphocytes), MCR (monocytes), and LCR (granulocytes) WBCs;
and hemoglobin were assessed at 6 h and 2, 5, 7, and 12 days.
FIG. 2. Flow cytometry analysis of T cells in STZ-induced diabetic mice. CD3+, CD4+, CD25+Foxp3+ (gated in the CD4+ population), and CD8+ cell
percentages were analyzed in the blood at day 3 (D3), 7 (D7), and 12 (D12) and in the spleen at days 3 (D3) and 13 (D13). Blood from 15 naive and
8 STZ-induced diabetic mice was analyzed. Spleens of eight naive and ﬁve STZ-induced diabetic mice were analyzed. Median and the range are
shown. A nonparametric Kruskal-Wallis test was performed. *P < 0.05, **P < 0.01, ***P < 0.001.
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FIG. 3. The effects of STZ and acute hyperglycemia. The respective effects of STZ and hyperglycemia were analyzed in three different models. First
(A–D), C57BL/6 mice were transplanted 3 days after STZ administration with 400 islets equivalent under the left kidney capsule. Sixty days after Tx,
a nephrectomy (graftectomy) was performed to induce diabetes without STZ. Absolute numbers of white blood cells (A) and percentage of
CD25+Foxp3+ Tregs gated in the CD4+ population (B) were assessed at different time points in the blood (days 0, 3, 7, 12, 21, 28, and 60 after STZ
administration and 60 + 3, 60 + 7, and 60 + 12 after nephrectomy). Absolute numbers of splenocytes (C) and percentage of CD25+Foxp3+ Tregs (D)
were assessed in the spleen before nephrectomy (day 60 [D60]) and after nephrectomy (day 60 + 13 [D60+13]). Second (E–H), RIP-DTR transgenic
mice were made diabetic by administration of DT. Absolute numbers of leukocytes were assessed in the blood at days 3, 7, and 12 (E) and in the
spleen at day 13 (D13) after DT administration (F). Percentage of Tregs in RIP-DTR transgenic mice was assessed at the same time points in the
blood (G) and in the spleen (H). Third (I–L), 3 days after STZ administration, an insulin pump was implanted subcutaneously to control the glycemia
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lipopolysaccharide (0.5 mg/mL), or anti-CD3e mAb (1 mg/mL, clone 145–2C11;
eBioscience). For in vitro suppression assays, CD4+CD25+ (Treg phenotype)
cells were isolated from spleens of naive (group 1) and diabetic mice 3 days
(group 2) and 13 days (group 3) after STZ administration. CD4+CD25+ (Treg
phenotype) and CD4+CD25– T cells (effector T cells) were isolated by CD4-
negative selection followed by CD25-positive selection using the CD4+CD25+
regulatory T-cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
CD4+CD25+ and CD4+CD25– T-cell purities were .90%. The in vitro sup-
pression assay was performed as followed: 5 3 104 puriﬁed CD4+CD25– ef-
fector T cells from naive mice were cocultured with 1 3 105 irradiated (3,500
rad) syngeneic splenocytes in the presence of anti-CD3e mAb (1 mg/mL).
Thereafter, CD4+CD25+ Treg from group 1 (naive mice), group 2 (diabetic
mice 3 days after STZ), and group 3 (diabetic mice 13 days after STZ) were
added at different CD4+CD25+:CD4+CD25– ratios (1:1, 1:2, 1:4, 1:8). On day 3,
cells were pulsed with 1 mCi [3H]thymidine for 18 h and harvested. Results
are expressed as count per minutes, showing one representative experiment
out of three.
RT-PCR for GLUT2 expression. RNA of splenocytes, CD4+ cells, CD4+CD25+
cells, islets, and the liver was extracted using the Qiagen RNEasy Mini Ex-
traction Kit (Qiagen, Hombrechtikon, Switzerland). Reverse transcription was
performed using the ImProm-II Reverse Transcription System (Promega,
Madison, WI), and cDNA was ampliﬁed with the GoTaq DNA polymerase
(Promega). Primer sequences are listed in Supplementary Table 1.
Transforming growth factor-b measurement. Plasma transforming growth
factor (TGF)-b concentrations were assessed at 6 h and 1, 2, 3, and 7 days after
STZ administration using the mouse/rat/porcine/canine TGF-b1 Quantikine
ELISA kit (R&D Systems, Minneapolis, MN). Whole blood was sampled from
the tail vein into heparinized tubes and centrifuged at 500g for 20 min at 20°C.
Plasma was stored at 220°C.
Histopathology and immunohistology. Nephrectomy (graftectomy) was
performed 10 days after islet Tx. Kidneys were preserved in formol 10% and
then embedded in parafﬁn and sectioned. Parafﬁn sections were used for
hematoxylin and eosin staining. For insulin staining, parafﬁn sections were
incubated using guinea pig antiporcine insulin antibody (DAKO A564; DAKO,
Glostrup, Denmark) and subsequently with goat anti-guinea pig Alexa 488–
conjugated antibodies (Invitrogen, Basel, Switzerland). For Foxp3 staining,
parafﬁn sections were prepared as previously described using biotinylated
anti-Foxp3 mAb (clone FJK-16s; eBioscience) and developed with streptavidin/
HRP (DAKO PO397) (9). Slides were analyzed under an axiocam microscope
(Zeiss; Axiophot, Göttingen, Germany).
Statistical analysis. Prism softwarewas used for statistical analysis (GraphPad
Software, Inc., San Diego, CA). The nonparametric Kruskal-Wallis test (and
Dunn’s method as a post-test) was used for analyzing in vivo data, whereas in
vitro assays were analyzed using one-way ANOVA testing and Bonferroni’s
multiple testing correction. Graft survivals between groups were compared
using the log-rank test.
RESULTS
STZ-induced diabetic mice are lymphopenic. C57BL/6
mice became diabetic between 48 and 72 h after STZ
injection (220 mg/kg) (Fig. 1A) and rapidly lost weight as
a consequence of dehydration (Fig. 1B). Total splenocyte
counts were assessed on days 3 and 13 after STZ admin-
istration, showing a rapid depletion (Fig. 1C). The size of
the spleen was also signiﬁcantly diminished after 13 days
(Fig. 1D). Lymphoid organs revealed a similar reduction
with respect to cell numbers and size (data not shown).
The proﬁle of peripheral blood leukocytes was further
examined using an automated hematocytometer (Table 1).
The number of small WBCs corresponding to the lym-
phocytes (SCR) was decreased as soon as 6 h after STZ
administration, whereas the number of middle and large
WBCs corresponding to monocytes (MCR) and gran-
ulocytes (LCR), respectively, remained stable over time.
The same was true for erythrocytes and hemoglobin
(Table 1). STZ is known to be hepatotoxic and nephrotoxic.
Thus, a strong inﬂammatory response to STZ within these
organs as well as in the pancreas, the peritoneum, or the
heart could explain the observed lymphopenia. However,
hematoxylin and eosin staining of these organs performed
3 days after STZ administration did not show any signiﬁcant
lymphocytic inﬁltration (Supplementary Fig. 1). In conclu-
sion, STZ-induced diabetes led to a strong lymphopenia in
the blood and in the spleen, which was not due to leukocyte
redistribution and organ inﬁltration.
We further assessed by ﬂow cytometry the relative dis-
tribution of the leukocyte subsets in circulation and in the
spleen after STZ administration. Frequencies of CD3+, CD4+,
Foxp3+CD25+ (gated within the CD4+ cells), and CD8+ cells
were determined according to their respective isotype
controls (Fig. 2 and Supplementary Fig. 2). Interestingly, the
percentage of Foxp3+CD25+ Tregs signiﬁcantly increased in
both compartments, at day 3 in the spleen and at day 7 in
the blood, although total numbers did not differ from naive
mice. Similar results were found in lymph nodes (data not
shown). Moreover, the proportion of CD8+ cells was di-
minished in the blood but not in the spleen 3 days after STZ
administration (Fig. 2), whereas the B-cell levels remained
unchanged (data not shown). Taken together, STZ-induced
diabetes is associated with a higher frequency of Tregs in
the blood and secondary lymphoid organs and reduced
numbers of CD8+ T cells in the blood.
Distinct effect of STZ and acute hyperglycemia on
leukocytes. To understand the respective roles of STZ
and acute hyperglycemia in the observed induction of
lymphopenia and increase in Treg frequencies, three dif-
ferent models were established. First, diabetic mice were
transplanted with syngeneic islets under the kidney cap-
sule 3 days after STZ, which reinstalled normoglycemia in
these animals (data not shown). After 60 days, the kidney
bearing the islets was removed to induce diabetes without
STZ. Total leukocyte number and Treg frequencies were
measured in the blood at day 60 and day 60 + 3, +7, and
+12 after nephrectomy (Fig. 3A and B) and in the spleen
before nephrectomy (day 60) and after nephrectomy (day
60 + 13) (Fig. 3C and D). Treg frequencies increased only
after STZ administration, although both STZ and hyper-
glycemia induced lymphopenia. Second, RIP-DTR trans-
genic mice, which express the coding sequence of the DT
receptor under the control of an insulin promoter, were
made diabetic by DT administration (18). Total leukocyte
numbers were decreased in the blood (Fig. 3E) and in the
spleen (Fig. 3F), although the frequency of Tregs remained
unaffected in both compartments (Fig. 3G and H), in-
dicating that diabetes induction only is sufﬁcient to deplete
leukocytes. Third, the effect of long-term hyperglycemia
was tested in STZ-induced diabetic mice. Three days after
STZ administration, an insulin pump was implanted sub-
cutaneously. This procedure allowed us to control the
glycemia for approximately 20 days (Fig. 3I). Thereafter,
the insulin pump was ineffective and the mice became
diabetic again. Consistent with the two previous models,
the number of leukocytes was decreased in the spleen at
day 44 compared with naive mice (Fig. 3J). However, the
initial increase of the Treg frequency was not maintained
in the blood and in the spleen in these mice, suggesting
a critical role of STZ in modulating the Treg compartment
for;20 days. Thereafter, the insulin pump was ineffective, and the mice became diabetic again (I). Absolute numbers of splenocytes were assessed at
day 44 (D44) after STZ (J). Treg percentage was calculated in the blood at days 3, 7, 12, 21, 35, and 44 (K) and in the spleen at day 44 (D44) (L). The
median and the range are shown.
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(Fig. 3K and L). Thus, the increase in Treg percentage
correlated with STZ administration, whereas the hyper-
glycemia alone also induced leukopenia.
STZ is toxic for leukocytes in vitro. The effect of STZ
was further tested on splenocytes in vitro. As a positive
control, we ﬁrst exposed C57BL/6 islets with 4.4 mmol/L STZ
in 10% FCS medium or citrate buffer control medium for
1 h. This concentration was based on previous work eval-
uating the effect of STZ on islets in vitro (18). Thereafter,
islets were washed and maintained in culture for 24 h
in 10% FCS medium. STZ conditioned islets showed a
typical necrotic aspect with loss of the integrity of the
collagen capsule. In contrast, the morphology of islets
cultured for 1 h in citrate buffer remained intact after 24 h
(Supplementary Fig. 3A). These ﬁnding were conﬁrmed by
7AAD staining of disrupted islet cells (Supplementary Fig.
3B). Splenocytes were harvested from Foxp3 knock-in mice
and cultured for 1 h in STZ or citrate buffer–conditioned
medium. Thereafter, the cells were washed and analyzed
for 7AAD 0, 2, and 5 h after STZ/citrate exposition. STZ-
conditioned splenocytes ﬁrst shifted toward apoptosis at 2 h
and then mainly toward death at 5 h (Fig. 4A). These results
were conﬁrmed by trypan blue staining (data not shown).
Percentage of 7AAD+ cells in CD4+, Foxp3+, CD8+, and B
cells were further analyzed at time point 2 h after STZ or
citrate exposition to determine which cell subtypes were
more sensitive to STZ. The ratio of 7AAD+ CD8 and B cells
after STZ exposure compared with the citrate buffer control
was 4.5 and 4.1. In contrast, this ratio was only 1.3 and 1.2
for CD4+ and Treg, respectively (Fig. 4B). Moreover, CD8
and B cells stained positive for Annexin V 2 h after expo-
sure to STZ, suggesting that cell death was mediated
through apoptotic pathways (Fig. 4C). Functional tests were
also performed. The proliferation of splenocytes stimulated
with concanavalin A, lipopolysaccharide, or anti-CD3e mAb
was abolished if exposed for 1 h to STZ (Fig. 4D). The sus-
ceptibility of Treg to STZ was further analyzed in vitro.
Puriﬁed CD4+CD25+ T cells were incubated for 1 h with
STZ or citrate buffer. Thereafter, an in vitro suppression
assay was performed. CD4+CD25+ T cells still suppressed,
although not completely, anti–CD3e-stimulated proliferation
of CD4+CD25– T cells (Fig. 4E). Furthermore, we analyzed
GLUT2 mRNA in the subsets of lymphocytes, since it is
one of the main pathways for uptake of STZ (1). Neither
splenocytes nor puriﬁed CD4+CD25– nor CD4+CD25+ cells
were positive for GLUT2 mRNA (Fig. 4F).
To test whether high levels of glycemia directly affect
their viability and proliferation, splenocytes harvested
from naive mice were incubated with increasing amounts
of glucose (11, 22, and 33 mmol/L) for 24 h. Hyperglycemia
failed to induce signiﬁcant toxicity, as shown by 7AAD
staining (Supplementary Fig. 3C). Moreover, high levels of
glucose in the medium did not affect the proliferation of
splenocytes (Supplementary Fig. 3D). Altogether, these
results showed a high susceptibility of CD8 and B cells to
STZ, whereas Tregs were partially resistant. These effects
were not mediated via the GLUT2 transporter, suggesting
that STZ enters into lymphocytes by other pathways. Fi-
nally, the observed lymphopenia in response to hypergly-
cemia in vivo was not explained by a direct lymphotoxic
effect of glucose in vitro.
Tregs of STZ-induced diabetic mice are suppressive
in vitro and proliferate in vivo. The suppressive func-
tion of CD4+CD25+ (Treg phenotype) puriﬁed from naive
(group 1) or diabetic mice 3 (group 2) and 13 (group 3)
days after STZ administration was then tested in vitro. The
purity of CD4+CD25+ T cells from STZ-induced diabetic
mice was similar to those isolated from naive mice (data not
shown). No difference was found with respect to the in vitro
suppressive capacity of CD4+CD25+ Tregs, neither at day 3
nor at day 13 after STZ administration in comparison with
Tregs of naive mice. These results suggest that Tregs in di-
abetic mice retain their suppressive function in vivo (Fig. 5A).
The proliferation rate of Tregs was further analyzed in the
blood and in the spleen. Ki67-positive cells were gated in
CD8+, total CD4+, and CD4+CD25+Foxp3+ T cells. Treg pro-
liferation increased at days 5 and 7 in the blood (Fig. 5B).
Moreover, TGF-b measured in the plasma of STZ mice was
also enhanced at day 7 (Fig. 5C). In the spleen, no difference
was detected in Treg proliferation between days 3 and 7,
although their basal proliferation rate was higher than that
of total CD4+ cells (Fig. 5D). In addition, Treg proliferation
accounted for up to 50% of the total CD4+ cell proliferation
(data not shown). Thus, these results demonstrate that the
proliferative response of Tregs to STZ in vivo also contrib-
utes to the increase of their frequency in the blood but not in
the spleen.
STZ-induced diabetic mice are immunosuppressed. We
further investigated the effect of STZ-induced lymphopenia
and increased percentage of Tregs on allograft rejection.
First, STZ-induced diabetic and naive C57BL/6 mice were
transplanted with BALB/c pancreatic islets. Ten days after
Tx, the mice were killed and grafts were analyzed by im-
munohistology. Islets were completely destroyed in naive
mice (Fig. 6D and E), whereas in STZ-induced diabetic
mice, the islets were stained positive for insulin (Fig. 6A and
B). The median graft survival (MGS) in STZ-induced di-
abetic mice was 17.5 days (data not shown). Moreover,
higher numbers of Foxp3+ cells were found within the graft
of diabetic mice compared with naive mice (Fig. 6C–F).
To conﬁrm these results in a more stringent Tx model,
STZ-induced diabetic and naive C57BL/6 (H2b) mice were
grafted with BL/6xDBA/2 F1 (H2bxH2d) skin 3 days after
STZ administration. At the same time, an insulin pump was
implanted subcutaneously in STZ-induced diabetic mice to
correct the blood glucose, allowing the mice to survive.
Skin grafts were rejected approximately 1 week later in
STZ-induced diabetic mice (MGS 20 days) compared with
untreated mice (MGS, 14 days) (Fig. 6G and H). These
results demonstrate that STZ treatment delays allogeneic
graft rejection and that this immunosuppressive effect is not
speciﬁc to islet Tx. To further conﬁrm the immunosup-
pressive effect of STZ-induced diabetes, BL/6xDBA/2 F1
(H2bxH2d) skin grafts were transplanted to naive and STZ-
induced diabetic mice (+ insulin pump) treated with anti-
CD154 mAb (MR1). MR1 alone had a similar effect than STZ
with an MGS of 18 days. MR1 therapy signiﬁcantly improved
the skin graft survival in STZ-induced diabetic mice (MGS
38 days, P , 0.0001), demonstrating that diabetes induction
with STZ potentiates the immunosuppressive effect of the
MR1 (Fig. 6G). Thus, these results suggest that many results
obtained in STZ-induced diabetic mice with respect to long-
term graft tolerance may be overestimated.
DISCUSSION
The goal of this study was to analyze the effect of STZ on
the immune system and the outcome of allotransplantation
with respect to graft rejection and tolerance. Our results
demonstrate that STZ-induced diabetic mice are immuno-
suppressed compared with naive mice, leading to prolonged
islet and skin allograft survival. Two mechanisms are put
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FIG. 4. Effect of STZ on leukocytes in vitro. A: Splenocytes were harvested from Foxp3 GFP knock-in mice and cultured for 1 h in 4.4 mmol/L STZ or
control citrate-conditioned medium (10% FCS). 7AAD+ cells were analyzed by ﬂow cytometry 0, 2, and 5 h after STZ exposition. One representative
experiment out of four is shown. B: Percentage of 7AAD+ cells in CD4+, Foxp3+, CD8+, and B cells were further analyzed 2 h after STZ or citrate
exposition to determine which cell subtypes were more sensitive to STZ. The results were calculated as followed: % of 7AAD+ cells (STZ condition)
divided by percent of 7AAD+ cells (citrate condition). The mean and SD of four separate experiments pooled together are shown and analyzed by one-
way ANOVA. C: CD8+ and B220+ cells were analyzed for Annexin V expression 2 h after STZ or citrate exposition. One representative experiment out of
four is shown. D: After exposition to STZ or citrate-conditioned medium, splenocytes were stimulated with concanavalin A, lipopolysaccharide, or anti-
CD3e for 3 days, and their proliferation rate was assessed by [3H]thymidine incorporation. The mean and SD of one representative experiment (per-
formed in triplicate) out of three is shown and analyzed by one-way ANOVA. E: Puriﬁed CD4+CD25+ cells were cultured for 1 h in 4.4 mmol/L STZ or
citrate-conditioned medium (10% FCS). Thereafter, an in vitro suppression assay was performed. CD4+CD25+ T cells from naive or STZ-induced diabetic
mice (day 3 [D3] or 13 [D13]) were added at different CD4+CD25+:CD4+CD25– ratios (1:1, 1:2, 1:4, 1:8). The mean and SD of one representative ex-
periment (performed in triplicate) out of three is shown and analyzed by one-way ANOVA. F: GLUT2 mRNA was analyzed in splenocytes, puriﬁed CD4+
cells, and Tregs. Puriﬁed islets and liver tissue were used as the control. Two separate experiments were performed. *P < 0.05, ***P < 0.001.
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forward to explain the observed immunosuppression asso-
ciated with STZ treatment: the induction of lymphopenia
and a shift toward Tregs.
Consistent with previous reports, STZ was directly toxic
for lymphocytes, inducing apoptosis in vitro, and was re-
sponsible for early depletion of blood and spleen lym-
phocytes in vivo. A study published over 25 years ago (2)
had shown that incubation of splenocytes with STZ in vitro
abrogated their capacity to proliferate in response to var-
ious stimuli. However, these data were not further in-
vestigated since then with respect to the characterization
of the different susceptibility of lymphocytes subset to
STZ. It is noteworthy that, in our study, CD8+ T cells and B
cells were particularly sensitive to STZ toxicity in vitro.
This observation is in line with the decrease in CD8+ T-cell
numbers in the peripheral blood of STZ-treated mice. Be-
cause CD8+ T cells are known to play a critical role in
b-cell autoimmunity and rejection, direct CD8+ depletion
induced by STZ administration may contribute to the bet-
ter islet engraftment described after Tx. Indeed, NOD mice
treated with anti-CD8 mAb or small doses of STZ in early
life are protected from spontaneous diabetes (5,19,20). In
addition, our results demonstrate that the uptake of STZ
into lymphocytes occurs independently of the transporter
GLUT2, which is known to be the main pathway for STZ
uptake into b-cells (21). Because STZ is a glucose analog
and lymphocytes depend on glucose (22), several other
active and passive glucose transporters such as GLUT1
could be implicated. Thus, further investigation is warranted
to determine the receptors responsible for the transport of
STZ into lymphocytes and its toxic effects that ﬁnally lead to
their death.
Importantly, STZ is not the only factor leading to T-cell
depletion in STZ-induced diabetic mice. In agreement with
similar observations in various animal models of diabetes
(7,23), we demonstrate here that acute hyperglycemia
induces lymphopenia. Three different models of diabetes
were used, and all induced lymphopenia independently of
STZ: 1) new-onset (diabetes induction in RIP-DTR mice),
2) recurrent (nephrectomy of transplanted syngeneic islets),
and 3) continuous hyperglycemia (STZ-induced diabetic mice
treated with an insulin pump). However, the mechanisms
leading to hyperglycemia-induced lymphopenia remain
poorly deﬁned. Our results support the notion that indirect
pathways are responsible for the observed lymphopenia in
vivo because exposure of lymphocytes to high levels of
glucose in vitro did not signiﬁcantly affect their viability or
their capacity to proliferate. Diabetes onset is known to be
associated with high serum levels of glucocorticoids, which
are lymphotoxic (24). A potential role of glucocorticoids in
hyperglycemia-induced lymphopenia is further supported
by the fact that adrenalectomy before diabetes induction
hampered the increase of glucocorticoids and the associ-
ated lymphopenia (7,25). Others showed an adrenal hy-
persensitivity preceding the blood hypercorticism (26).
Thus, it is likely that dehydration in diabetic mice induces
antidiuretic hormone release, which in turn directly sensi-
tizes the adrenal glands to produce glucocorticoids (27).
Nevertheless, this hypothesis still remains to be conﬁrmed
in STZ-induced diabetic mice.
The second important observation in STZ-induced di-
abetic mice was the increase of Treg frequencies in the
spleen, the peripheral blood, and also in lymph nodes (data
not shown). In addition, Tregs were detected in islet allo-
grafts after STZ administration, with longer graft survival in
STZ-induced diabetic mice compared with control mice.
On the basis of these observations and similar reports, we
and others suggested a role of Tregs in the control of im-
mune responses after allo- and xenogeneic islet Tx (9,13) or
solid organ Tx (28,29). It is not necessarily an increase of
the absolute numbers of Tregs but rather a favorable shift
of the Treg/T effector cell ratio that is “tolerogenic” (30,31).
Importantly, the relative increase of Tregs correlated
speciﬁcally with the administration of STZ and was not a
consequence of hyperglycemia, since neither early (DT
administration to RIP-DTR mice) nor late (removal of islet
FIG. 5. Treg suppression in vitro and proliferation in vivo. A: CD4+CD25+ cells were puriﬁed from naive (group 1) and STZ-induced diabetic mice at
day 3 (group 2) (D3) and day 13 (group 3) (D13). The results of an in vitro suppression assay, as described in RESEARCH DESIGN AND METHODS, are
shown as mean and SDs. One representative experiment out of three is shown. B: Ki67 expression was analyzed in the blood in CD4+ (total
population), CD8+, and Foxp3+ T cells at day 3 (D3), 5 (D5), and 7 (D7) after STZ administration (n = 8–20 per group/time point). C: Plasma TGF-b
concentrations were assessed at 6 h and 1, 2, 3, and 7 days (1d, 2d, 3d, 7d) after STZ administration (n = 6). D: Ki67 expression was analyzed in the
spleen at days 3 and 7 after STZ administration (n = 6). The median and the range are shown in B, C, and D and were analyzed with the Kruskal-
Wallis test. ***P < 0.001.
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grafts long after STZ diabetes induction) hyperglycemia
affected the percentage of Tregs. The relative increase of
Tregs was also associated with a higher level of Treg pro-
liferation in the blood. Finally, TGF-b, which has been
shown to convert naive CD4+CD25– T cells into CD4+CD25+
Tregs in vitro, was increased in the peripheral blood of mice
3 and 7 days after STZ injection (32). Parallel ﬁndings were
reported after lymphocyte depletion using monoclonal
antibodies (either anti-CD3 antibody therapy [33,34] or
Campath [anti-CD52] [35,36]). Thus, it is likely that a pro-
found depletion of T cells mediated by STZ, anti-CD3, or
Campath may lead to an increased proliferation of Tregs.
More recently, a predominant role for the production of
systemic TGF-b was attributed to macrophages and dendritic
cells (37). Furthermore, the association between apoptotic
cell phagocytosis and TGF-b2mediated Treg expansion has
led to the development of experimental therapies consisting
in intravenous apoptotic cell infusion (38,39). Taken together,
one might speculate that Treg expansion in STZ-induced
diabetic mice is mediated by TGF-b in an apoptosis-prone
lymphopenic environment, but this hypothesis warrants
further testing.
Overall, this study emphasizes the immunomodulation
that occurs after STZ administration. Indeed, diabetic mice
display a severe lymphopenia combined with a relative
increase of Tregs in the blood, spleen, and lymph nodes.
These are important changes to consider and to discuss in
future studies using STZ-induced diabetic mice, in partic-
ular, in the setting of tolerogenic protocols for islet Tx.
Because our work also shows that acute hyperglycemia is
sufﬁcient to induce lymphopenia, it is likely that any model
that is based on diabetes induction is biased toward im-
munosuppression. In conclusion, the results of previous
studies of Tx tolerance induction and immunosuppressive
protocols might be overestimated using STZ-induced di-
abetes models and need to be reinterpreted in light of the
present ﬁndings.
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